Spondyloarthritis
Janus Kinase (JAK) Inhibitors
Ace the Case: A 35-Year-Old Female Dentist With Back Pain
There is no commercial support for this activity.
More JAK inhibitors ‘coming down the pike’ despite poor understanding of mechanism
The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.
European Medicines Agency recommends bimekizumab in two new indications
The European Medicines Agency has recommended granting marketing authorization for bimekizumab for the treatment of adults with axial spondyloarthritis and active psoriatic arthritis, according to a UCB press release.
Postpartum patients may be at risk for false-positive axial spondyloarthritis diagnosis
As many as 41% of patients who are 1 year postpartum meet the ASAS criteria for sacroiliitis, which could lead to false positive diagnoses of axial spondyloarthritis, according to data published in Arthritis & Rheumatology.
TNF inhibitors ‘not always’ standard of care in spondyloarthritis
SCOTTSDALE, Ariz. — Although TNF inhibitors can work “across the spectrum” in spondyloarthritis, they are “not always” the standard of care, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.
Two-thirds of spondyloarthritis society members use social media for work
As many as 66% of surveyed members of the Assessment of Spondyloarthritis International Society use social media for “work-related purposes,” including collaboration, according to data published in the Journal of Medical Internet Research.
Hoping for a biosimilar ‘sea change’: Rheumatologists weigh 2023 end of Humira exclusivity
In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.
NSAIDs show ‘deleterious’ impact on fertility women with spondyloarthritis
Among women with spondyloarthritis, those who are of older age and use of NSAIDs during preconception demonstrate longer time to conception, according to data presented at ACR Convergence 2022.
Patients with IMIDs demonstrate lower, less durable COVID-19 vaccine response
Patients with immune-mediated inflammatory diseases demonstrate a lower, less durable COVID-19 vaccine response and are at risk for losing humoral immune protection, according to data published in The Lancet Rheumatology.